Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3025 (Published 10 May 2013)
Cite this as: BMJ 2013;346:f3025

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Anne Gulland
  1. 1London

More girls in developing countries will have access to vaccination against human papillomavirus (HPV), the infection responsible for most forms of cervical cancer, after drug companies agreed to supply the vaccine at a much lower price.

The Global Alliance for Vaccines and Immunisation (GAVI Alliance), a public-private partnership whose aim is to increase access to vaccines in developing countries, has negotiated with the companies Merck and GlaxoSmithKline for vaccines to be priced at $4.50 (£2.90; €3.40) and $4.60 a dose, respectively. The previous lowest price for developing countries was around $13 a dose.

GAVI hopes that by 2020 around 30 million girls in 40 countries will have access to the vaccine and that the cost of the vaccine will reduce further as demand for it rises.

Of 15 countries …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL